Dostarlimab

Jemperli

BrazilAuthorisedAuthorised 2 Mar 2022

In other countries

The same active substances on other registers, the same brand first.

JemperliCanada · 50 MG / ML · Solution · Glaxosmithkline INCSame brand
JEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONSpain · 500 mg · concentrado para solución para perfusión · Glaxosmithkline Trading Services LimitedSame brand
Jemperli 500 MG Concentrado Para Solucion Para PerfusionSpain · 500 mg · concentrado para solución para perfusión · Glaxosmithkline (Ireland) LimitedSame brand
JemperliEuropean Union · GlaxoSmithKline Trading Services LimitedSame brand
JemperliCroatiaSame brand
JemperliItaly · Soluzione per infusione · Glaxosmithkline Trading Services LimitedSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Dostarlimab

Jemperli

BrazilAuthorisedAuthorised 2 Mar 2022

Ask Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Jemperli 500 mg oplossing voor infusie

Netherlands · Oplossing voor infusie · GlaxoSmithKline Trading Services Limited

Jemperli Concentrate for Solution for Infusion 500MG/10MLSingapore · 500mg/10mL · infusion, solution concentrate · Glaxosmithkline Pte LTD

JemperliUnited States · 500MG/10ML · injectable · Glaxosmithkline

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Anvisa, Brazil

Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.

Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Dostarlimab
Register: Brazil (Anvisa)
Status: Authorised
Status in the register: Ativo
Authorised: 2 Mar 2022
Registration: 101070355
Marketing authorisation holder: Glaxosmithkline Brasil Ltda
Procedure: Registered